
bioAffinity Technologies Closes $3.2 Million Public Offering
Jersey City-based biotechnology firm bioAffinity Technologies has finalized a public offering of securities, securing $3.2 million in gross proceeds. The capital injection is earmarked to support the company's efforts in developing noninvasive diagnostic tools for the detection of early-stage lung cancer and associated pulmonary conditions.


























